Therapeutic Programs

Dimerix has identified over 30 novel GPCR heteromers that have not been disclosed in any literature. This information has enabled Dimerix to identify certain commercially attractive drug development and re-positioning opportunities.

Particular areas of interest relate to oncology, metabolic disorders, renal disease, cardiovascular and inflammatory disease.